---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-099560"
form_type: "8-K"
ticker: "CERO"
cik: "0001870404"
company_name: "CERO THERAPEUTICS HOLDINGS, INC."
filed_at: "2025-10-16T23:59:59+00:00"
generated_at: "2026-05-17T03:35:50.133086+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CERo Therapeutics closes $2.25M initial closing of Series E preferred stock financing, total $7M

## Summary
- Initial closing of 3,816 Series E preferred shares raised $2.25M gross proceeds on Oct 16, 2025.
- Amendment to SPA added an additional buyer and increased initial closing by $500k; total remains $7M.
- Series E preferred stock terms filed as Certificate of Designations on Oct 14, 2025.
- Remaining $4.75M to be funded at additional closings under the Securities Purchase Agreement.

## SEC filing metadata
- accession: 0001213900-25-099560
- form_type: 8-K
- ticker: CERO
- cik: 0001870404
- company_name: CERO THERAPEUTICS HOLDINGS, INC.
- filed_at: 2025-10-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1870404/000121390025099560/0001213900-25-099560-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1870404/000121390025099560/ea0261237-8k_cero.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-099560
- JSON: https://secwatch.observer/filing/0001213900-25-099560.json
- Plain text: https://secwatch.observer/filing/0001213900-25-099560.txt

## Key facts
- Governance Changes
  CERO THERAPEUTICS HOLDINGS, INC.: Filed Certificate of Designations establishing Series E convertible preferred stock (effective 2025-10-14).
  - Change: charter amendment
  - Effective: 2025-10-14
  source text: On October 14, 2025, the Company filed the Certificate of Designations of Rights and Preferences of the Series E Preferred Stock (the “Certificate of Designations”) for the purpose of designating and establishing the Company’s Series E convertible preferred stock, par value $0.0001 per share (the “Series E Preferred Stock”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1870404/000121390025099560/0001213900-25-099560-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.